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Abstract 
 Serological proteins of neuroblastoma were profiled and analyzed by ProteinChip-
SELDI-TOF MS technology with five types of protein chips. By comparing with normal 
control, a number of protein or polypeptide signals were found significantly and consistently 
different in their intensities (expression levels) in tumor sera. Interestingly, 9 polypeptide 
peaks in these proteomic features can be simultaneously detected with consistent variations by 
more than one type of protein chips. None of the expression differences of these 9 
polypeptides was found in similar comparisons between healthy controls and hepatomas. 
Preliminary protein identification showed hints for that some of these proteomic alterations 
may be closely related to the tumorigenesis of neuroblastoma. These results demonstrated the 
potential of serological biomarker identification for neuroblastoma by ProteinChip-SELDI 
technology.  
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Neuroblastoma is a malignant solid tumor frequently occurring in childhood. This 
disease has an incidence rate of one case per 8000 children, accounting for ~9% of all cancers 
in children under the age of 15 [Schwab et al., 2003]. Neuroblastoma arises from 
neuroectodermal cells derived from the neural crest and takes place in the adrenal medulla or 
paraspinal symphatetic nervous system [Schwab et al., 2003; Bown, 2001]. In general, infants 
less than one year old with neuroblastoma present with lower stage and less aggressive 
disease, which are usually chemosensitive and thus curable [Bown, 2001]. However, in 
children over one year old, the disease is often much more aggressive, metastatic and 
chemoresistant, and therefore has a high mortality rate [Bown, 2001]. The biological 
mechanism underlying this substantial clinical heterogeneity of neuroblastoma is still elusive.  
 To improve the understanding of neuroblastoma, many genetic and biological features 
have been investigated [Riley et al., 2004]. A number of studies have also been performed to 
identify tumor markers for facilitating the screening, diagnosis, prognosis, or monitoring of 
the disease to improve cure rates [Riley et al., 2004]. However, specific and sensitive 
diagnostic and prognostic markers have not been found yet. A recent study also revealed that 
relapse or progression in neuroblastoma cannot be reliably detected by monitoring the current 
tumor markers alone [Simon et al., 2003]. This presents a great need of continued effort to 
identify useful biomarkers for designing novel diagnostic tools and therapeutic strategies. 
 As an emerging powerful biological research technique, proteomics has recently 
become a key tool in the identification of biomarkers and disease targets [He et al., 2003; Zhu 
et al., 2003; Petricoin et al., 2003]. An advantage of proteomics is its ability to simultaneously 
inspect the whole proteome so that correlated proteins altered in expression and modification 
corresponding to a disease condition can be identified in a single experiment. This makes it 
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possible to combine several protein markers together to form an index with higher sensitivity 
and specificity in the detection and monitoring of disease. 2D-gel based proteomics has been 
extensively used to study disease pathogenesis and to identify novel potential biomarkers for 
various cancers including neuroblastoma [Campostrini et al., 2004; Wimmer et al., 1996; Shin 
et al., 2003; Zhou et al., 2003]. However, 2D-gel electrophoresis has its limitation in protein 
separation. For example, proteins that have molecular weights (MW) less than 10 kDa and 
isoelectric points (pI) less than 3 and higher than 11 cannot be separated or well displayed in 
gels. As a complementary tool, ProteinChip SELDI-TOF technology is much useful in 
analyzing proteins with low MWs covering the entire pI range. Other advantages of 
ProteinChip SELDI-TOF include its high sensitivity and straightforwardness especially in 
examining body fluids such as serum samples. In this study, serum specimens from 
neorublastoma patients were analyzed by using five types of protein chips. By comparing the 
serological protein profiles between patients and healthy controls, a number of proteomic 
features were found significantly altered. Some of the alterations can be detected in more than 
one type of protein chips simultaneously. None of these expression differences was found in 
similar comparisons between normal samples and hepatomas. The interesting results 
demonstrated that serological biomarker identification by ProteinChip SELDI TOF 
technology for neuroblastoma is promising.  
 
 5
METHODS AND EXPERIMENTAL PROCEDURES 
Patient Materials 
With patients’ consent, we collected blood samples from neuroblastoma patients at the 
Queen Mary Hospital, Hong Kong. The study was approved by the research ethics committee 
of the University of Hong Kong. Since few neuroblastoma cases were available, we only 
included 5 serum samples from patients admitted in Queen Mary Hospital in last two years. 
Table 1 lists the patients’ information and histology. All neuroblastoma cases were confirmed 
histologically, with three at stage IV, one at stage III and one at stage II. Bone morrow 
metastasis was found at all the advance stages of IV and III. Serum samples from 10 healthy 
subjects were used as normal control. For comparison, another sample group containing 8 
normal and 8 hepatoma sera was recruited and subjected to similar screening. All blood 
samples were distributed into 50µl aliquots and were stored at –80 °C before assay.  
 
ProteinChip Analysis of Serum Samples 
Five types of protein chips including IMAC3, WCX2, SAX2, H50 and NP20 from 
Ciphergen Biosystems (Frement, CA, USA) were used in the protein profiling of the serum 
samples. These protein chips have different surface affinity properties with IMAC3 for metal-
binding proteins, WCX2 (weak cation exchanger) for positive-charge molecules, SAX2 
(strong anion exchanger) for negative charge molecules, H50 for hydrophobic peptides and 
NP20 (normal phase) for general binding of proteins. The IMAC-Cu metal binding chip was 
observed to give the most signals.  
Each serum fraction was thawed and pretreated before loading. Serum sample of 3 µl 
in an eppendorf tube was diluted into 6 µl of U9 solution (9 mol/l urea, 2% CHAPS, 50 
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mmol/l Tris-HCl, pH 9.0), incubated for 30 min, and mixed every 5 min in between when 
incubating on ice or shaken gently and continually in a cold room. After vortexing, each 
sample was diluted in 1:36 with corresponding binding buffers. Then 10 µl mixed serum 
fraction was spotted onto each ProteinChip arrays with variety of chemical surfaces in 
duplicate.  
Before spotting, IMAC-Cu ProteinChip was incubated with 10 µl of 0.1 mmol/l 
CuSO4 solution for 10 min in a humid chamber. This was repeated twice. The chips were then 
incubated at room temperature for 30 min on a shaker. After incubation, non-bound proteins 
and other contaminants were removed by washing with buffers for three times. These buffers 
were 0.05% Triton 100 + 250 mmol/l Nacl in PBS for IMAC-Cu ProteinChip arrays, 50 mM 
NaAOc (pH 4.0) for WCX2 ProteinChip arrays, 0.05% Triton 100 in 50 mmol/l Tris-HCl (pH 
8.0) for SAX2 ProteinChip arrays, 10% acetonitrile for H50 and 0.1% trifluoroacetic acid for 
NP20 ProteinChip arrays. Finally all chips were washed with MilliQ-deionized water for four 
times to remove interfering substances such as salts and detergents. On drying, 0.5 µl of 
saturated energy absorbing molecule solution [α-cyano-4-hydroxycinnamic acid in 50% 
acetonitrile (v/v), 0.5% trifluoroacetic acid (v/v)] was added two times and the chips were 
allowed to air-dry.  
 
SELDI-TOF MS and Data Analysis 
Mass spectrometric analysis was performed by SELDI-TOF mass spectrometry in a 
PBS-II ProteinChip reader (Ciphergen Biosystems) according to an automated data collection 
protocol. This includes an average of 255 laser shots to each spot with a laser intensity of 240 
and 265, respectively, dependent on the measured region (low = 2–20 kDa and high = 20–200 
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kDa, respectively). The detector was run at a sensitivity of 9. Spectral analysis was carried out 
using the ProteinChip software version 3.1 (Ciphergen Biosystems). All mass spectra were 
normalized to have the same total ion current. Cluster analysis of the detected signals and the 
determination of respective p values were carried out with the Biomarker Wizard Program 
(Version 3.0; Ciphergen Biosystems). For p value calculation, spectra with at least 10 signals 
in the range between 2 kDa and 20 kDa exhibiting a signal-to-noise ratio of at least 5 were 
selected and analyzed with the Mann-Whitney U test for non-parametric data sets. 
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RESULTS AND DISCUSSION 
 In order to comprehensively analyze the serological proteins, five types of protein 
chips, H50, IMAC3, NP20, SAX2 and WCX2, were used for the protein profiling of the 
serum samples from neuroblastoma patients and healthy subjects. Figure 1 shows 
representative protein profiles from 1.5 – 20 kDa detected by the five protein chips for the 
tumor and normal sera side by side. While the protein profiles among different chips are 
largely different, some proteomic signals can be visualized with more than one type of chips. 
Within each type of protein chip, significant differences in proteomic features between tumor 
and normal samples were evident.  
 When detailed cluster analyses were performed on the polypeptide peaks for each 
chip, a number of different features with a statistical significance were presented. Since only 
five cases of serum samples in tumor group were used in this study, we applied highly 
restricted parameters on selecting significant changes in protein expression. Only those 
polypeptide bands that varied more than 3 fold in intensity with p values less than 0.05 were 
regarded as significant alterations. Under this condition, ten protein features showing 
significantly different in intensity between tumor and normal sera were detected by 
ProteinChip H50 array, with eight peaks obviously decreasing and the other two substantially 
increasing in expression in neuroblastoma (Table 2). Likewise, Table 3-6 list other proteomic 
features that show significantly differences between tumor and normal control detected by 
other four types of protein chips. Respectively, 17 peaks with 6 decreases and 11 increases in 
tumor were identified by IMAC3 chip, 9 signals with 1 down and 8 up were visualized by 
NP20 chip, 8 features with 3 decreases and 5 increases were detected by SAX2 array, and 7 
bands with 3 decreases and 4 increases were distinguished by WCX2 chip.  
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 Interestingly, careful comparisons among the proteomic variations detected by 
different protein chips revealed that some different peaks can be visualized consistently by 
more than one array. Figure 2 displays an expended area of protein profiles containing the 
protein bands that show similar trends of alterations with the five types of chips. Peak at 
6934.3 Da cannot be detected by H50 array, but consistently shows enhanced intensities in 
tumor as measured by the other four protein chips. On the other hand, peak at 7767.6 Da can 
be seen by all five arrays and exhibits consistent decrease in expression in tumor sera. Other 
peaks that can be detected by more than one chip include those at 4058.65, 4215.34, 6919.62, 
8764.86, 9286.89, 13732.84, and 13868.63 Da, respectively. Table 7 lists all 9 protein 
features that can be identified by more than one array, in which two display constant increase 
and the other 7 were constantly depleted in tumor samples.   
 In a separated testing experiment, the positive control group containing 8 normal and 8 
hepatoma serum specimens was also subjected to similar analyses by the 5 protein chip 
arrays. When cluster comparisons were made between normal and hepatoma samples 
respectively for each type of chips, many differences were observed in terms of expression 
intensity (data will be published elsewhere) but none of them resembles the similar trend of 
alterations with the 9 polypeptide features detected in the neuroblastoma training group. Only 
one peak at 8762.29 Da, which was detected by SAX2 chip and exhibited 3.1-fold decrease in 
intensity with a p value of 0.011, is close to but may not be the same to the peak at 8764.86 
Da (see above). These results suggest that the proteomic features identified by the protein 
chips have a high specificity.  
 TagIdent tool in ExPASy molecular server (http://ca.expasy.org/tools/tagident.html) 
was used to search for a hint of the protein identities for these 9 polypeptide variants in 
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neuroblastoma. All possible protein IDs in HOMO SAPIENS database are listed in Table 7. 
For example, the peak with a mass of 4058.65 Da matches to defensin 6 precursor with a 
molecular weight (MW) of 4058.65 Da, and peak of 4215.34 Da matches to peptide YY-like 
precursor (PYY) (MW: 4215.76 Da). Some of these matches can have more than one entry. 
For instant, peak of 8764.86 Da matches to apolipoprotein C-III precursor (MW: 8764.67 Da) 
and complement C4 precursor (MW: 8764.07 Da). Other possible matches can be found in 
Table 7.  
 Although protein identification through TagIdent is basically preliminary, some 
proteins, if validated, are really related to tumorigenesis. For example, PYY is a regulatory 
neuropeptide that plays a significant role in inhibiting cancer cell growth [Tseng et al., 2002]. 
An under-expression of PYY has been implicated to the development and progression of 
colon adenocarcinoma and PYY treatment suppressed growth in pancreatic and breast tumors 
[Tseng and Liu, 2002]. PYY exerts action through its receptor [Freitag et al., 1995a]. 
Neuroblastoma cells have been shown to largely express PYY receptor [Kanatani et al., 1996; 
Freitag et al., 1995b; Miura et al., 1994], which may be a response to the less availability of 
PYY. The substantially decreased level of peptide YY-like precursor observed in current 
neuroblastoma sera may reflect the suppressed expression of the protein in cells, a relevant 
aspect in neuroblastoma development. Another low level polypeptide in neuroblastoma sera is 
platelet factor 4 precursor (PF4). PF4 is a CXC chemokine secreted by activated platelets and 
expressed during megakaryocytic differentiation. PF4 can inhibit endothelial cell proliferation 
in vitro and angiogenesis and tumor growth in vivo in experimental animals [Li et al., 2003; 
Long et al., 1990; Griffioen et al., 1999]. The marked decrease of PF4 level in cancer sera 
suggests the lacking activity of tumor inhibition of the protein in the patients.  
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 Two commonly and strikingly up-regulated proteins in neuroblastoma sera were 
identified as polyamine oxidase (PAO) splice variant 3 and glutathione S-transferase isoform 
3 (GSTM3). PAO splice variant 3 is an isoform of the PAO enzymes [Murray-Stewart et al., 
2002]. PAO takes part in the metabolism of polyamines, the organic cations with multiple 
functions in cell proliferation and differentiation [Thomas et al., 2003]. The regulation of this 
PAO enzyme has been implicated to have a role in facilitating apoptosis of cancer cells 
[Thomas and Thomas, 2003]. GSTM3 is a phenotype of the superfamily of GST enzymes 
involved in detoxification process. GSTs catalyze the glutathione conjugation reaction with 
eletrophilic compounds and carcinogens [Tsuchida et al., 1992]. The significant increase of 
GSTM3 level in neuroblastoma may correspond to the initiation of self protective machinery 
of cells in tumorigenetic process. The over-expressions of GSTs have been found in various 
cancers (For example [Lafuente et al., 1998; Li et al., 1997; Zhang et al., 1994]). 
 In summary, we have used five types of protein chips to examine the serum specimens 
from neuroblastoma patients and healthy subjects. Through SELDI-TOF mass spectroscopic 
analysis, a number of proteins or polypeptides were found to be significantly different in 
expression levels between the tumor and control sera. Some of these differences can be 
simultaneously distinguished by more than one type of protein chips, confirming that the 
alterations are stable and consistently detectable in serum. Possible protein identification 
revealed clues that these altered proteins may be related to the tumorigenesis of 
neuroblastoma. In addition, none of these alterations was found in the positive control group 
containing normal and hepatoma samples, indicating a high specificity for neuroblastoma. 
The present results demonstrate that ProteinChip SELDI-TOF technology is sensitive in 
identifying proteins/polypeptides changed in tumor serum and it is promising to combine 
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these altered protein features as potential biomarkers for clinical application. More serum 
specimens should be screened to test the sensitivity and specificity of the proteomic features 
as diagnostic biomarkers.    
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Table 1. Patients’ information and histology 
 
Patients Age Sex Stage Metastasis 
B370 2 F III + 
B378 3 M IV + 
B379 3 M IV + 
B381 4 M II - 
B405 6 M IV + 
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Table 2. Proteomic features showing significantly differences in expression detected by 
ProteinChip H50 array. 
 
Mass (Da) p Ctrl (Mean) Ctrl (SD) Tumor (Mean) Tumor (SD) Fold 
4215.79 0.0011 7.55 6.29 1.16 0.86 -6.5 
4349.39 0.0011 17.69 3.79 6.35 0.92 -3.0 
4389.11 0.0011 15.75 5.14 3.08 1.33 -5.2 
4716.36 0.0011 32.95 5.74 9.67 6.42 -3.4 
4818.34 0.0011 7.32 1.87 2.60 0.81 -3.0 
4964.85 0.0067 4.85 2.31 1.55 0.94 -3.1 
7569.77 0.0011 3.57 2.57 1.19 0.40 -3.0 
7616.28 0.0048 1.57 0.43 7.73 6.01 +4.9 
7766.53 0.0011 9.37 4.28 1.65 1.43 -5.7 
8291.16 0.0048 0.71 0.27 3.33 3.69 +4.7 
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Table 3. Proteomic features showing significantly differences in expression detected by 
ProteinChip IMAC3 array. 
 
Mass (Da) p Ctrl (Mean) Ctrl (SD) Tumor (Mean) Tumor (SD) Fold 
1236.05 0.0266 9.05 10.04 2.49 0.91 -3.6 
1851.80 0.0351 1.17 1.53 8.15 7.80 +7.0 
2025.87 0.0044 2.48 0.78 25.98 28.65 +10.5
2048.65 0.0114 1.29 1.06 7.11 6.45 +5.6 
2063.75 0.0203 0.96 0.86 6.38 8.75 +6.6 
2075.38 0.0452 2.86 1.48 9.61 8.13 +3.4 
2794.13 0.0084 4.66 2.65 23.70 18.46 +5.1 
3000.55 0.0203 1.57 1.12 5.51 5.48 +3.5 
3434.51 0.0268 1.19 0.96 5.60 6.32 +4.7 
4548.34 0.0153 5.03 2.02 30.32 18.62 +6.0 
6434.81 0.0015 7.09 3.30 0.78 0.58 -10.9 
6633.73 0.0016 18.28 11.68 3.13 1.76 -5.8 
7566.69 0.0044 20.23 13.57 4.39 3.27 -4.6 
7584.20 0.0268 11.17 11.55 2.03 1.04 -5.5 
9085.31 0.0350 14.94 6.72 46.10 26.06 +3.1 
10054.82 0.0350 0.69 0.53 3.13 3.29 +4.5 
15116.16 0.0350 16.36 15.43 2.55 1.31 -6.4 
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Table 4. Proteomic features showing significantly differences in expression detected by 
ProteinChip NP20 array. 
 
Mass (Da) p Ctrl (Mean) Ctrl (SD) Tumor (Mean) Tumor (SD) Fold 
3375.66 0.0245 1.53 1.25 6.16 5.32 +4.0 
4126.05 0.0027 2.09 1.81 6.23 2.85 +3.0 
4158.17 0.0192 5.51 4.26 23.52 19.15 +4.3 
4215.45 0.0246 15.12 9.02 4.78 6.29 -3.2 
4471.27 0.0037 3.26 1.88 9.87 4.46 +3.0 
4537.79 0.0148 0.83 0.62 7.00 12.20 +8.5 
6923.62 0.0087 1.38 0.91 10.17 8.85 +7.4 
6935.71 0.0066 1.41 1.27 15.15 11.47 +10.7 
6946.09 0.0036 1.27 0.56 11.90 9.71 +9.4 
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Table 5. Proteomic features showing significantly differences in expression detected by 
ProteinChip SAX2 array. 
 
Mass (Da) p Ctrl (Mean) Ctrl (SD) Tumor (Mean) Tumor (SD) Fold 
4058.63 0.0163 13.19 7.63 3.48 2.72 -3.8 
4158.56 0.0039 7.97 3.33 34.06 27.21 +4.3 
4214.58 0.0061 29.88 9.07 4.20 2.39 -7.1 
4651.16 0.0065 1.24 0.29 12.19 18.22 +9.8 
4780.32 0.0249 3.24 2.72 14.92 11.87 +4.6 
5825.13 0.0373 1.54 0.82 4.34 2.60 +3.0 
6919.49 0.0250 1.58 1.04 14.51 19.88 +9.1 
12442.05 0.0163 2.34 1.22 0.71 0.54 -3.3 
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Table 6. Proteomic features showing significantly differences in expression detected by 
ProteinChip WCX2 array. 
 
Mass (Da) p Ctrl (Mean) Ctrl (SD) Tumor (Mean) Tumor (SD) Fold 
3978.25 0.0065 1.22 0.46 5.81 6.73 +4.8 
4215.82 0.0062 23.85 8.16 3.97 6.27 -6.0 
4271.01 0.0373 7.28 5.71 2.23 1.25 -3.3 
6918.75 0.0249 3.25 1.09 15.60 13.77 +4.8 
7766.43 0.0163 25.58 14.14 7.94 9.89 -3.2 
11525.30 0.0249 0.64 0.33 10.66 18.76 +16.7
11987.32 0.0250 0.52 0.32 2.81 2.45 +5.4 
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Table 7. Fold differences (p values) for the polypeptide peaks detected co-currently by different types of ProteinChips. 
 
Mass (Da) H50  IMAC3 NP20 SAX2 WCX2 Possible ID (Da) 
4058.65   -2.6 (0.061) -3.8 (0.016)  Defensin 6 precursor (4058.65) 
4215.34 -6.5 (0.001)  -3.2 (0.024) -7.1 (0.006) -6.0 (0.006) Peptide YY-like precursor (4215.76) 
6919.62   +7.4 (0.009) +9.1 (0.025) +4.8 (0.025) Polyamine oxidase splice variant 3 (6916.88) 
6934.29  +2.8 (0.045) +10.7(0.006) +4.0 (0.054) +6.2 (0.078) GSTM3 protein (6933.16) 
7767.63 -5.7 (0.001) -2.4 (0.020) -2.7 (0.015) -2.3 (0.011) -3.2 (0.016) Platelet factor 4 precursor (7769.18) 
8764.86 -2.0 (0.001)   -2.3 (0.025) -1.5 (0.037) Apolipoprotein C-III precursor (8764.67) 
Complement C4 precursor (8764.07) 
9286.89  -2.2 (0.073) -2.4 (0.015)  -2.1 (0.037) ZFM1 protein (9287.76) 
13732.84    -2.6 (0.004) -1.9 (0.037) Tax interaction protein 1 (13734.71) 
13868.63 -2.5 (0.001) -2.7 (0.045)  -2.6 (0.016)  Myosin regulatory light polypeptide 9, 
isoform b (13865.55) 
C1orf21 (13865.33) 
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Figure 1. Representative protein profiles in 1.5 – 20 kDa range detected by the five protein chips for the tumor and 
normal sera side by side. N: normal control, T: tumor. 
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Figure 2. An expended area of protein profiles containing the protein bands that show similar trends of alterations 
with the five types of chips. N: normal control, T: tumor. 
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